Inicio > PIE > Resultado de la búsqueda

    Resultados: 3

    Defendendo incentivos alternativos para um sistema proativo de pesquisa e desenvolvimento farmacêutico: prompt COVID-19
    COVID-19 Series: Advocat- ing for alternative incentives for a proactive pharmaceutical R&D system: a prompt from COVID-19

    Yehia, Farah; Harb, Aya; El-Jardali, Fadi.
    Este documento apresenta recomendações importantes para melhorar o sistema farmacêutico de P&D, com base nas aprendizagens de doenças infecciosas emergentes anteriores e nas melhores práticas internacionais....
    COVID-19, Recursos en Salud, Acceso a Medicamentos Esenciales y Tecnologías Sanitarias, Antiinfecciosos, Preparación para una Pandemia, Industria Farmacéutica, Inversiones en Salud
    Texto completo

    The implementation of the bioequivalence certification policy in Chile: an analysis of market authorization data

    Kaplan, Warren A; Cárdenas, Jorge; Mansilla, Cristián; Tobar, Tatiana; Wirtz, Veronika J.
    PLoS One; 14 (5), 2019
    Affordability is a key barrier to access to medicines. Generic medicines policies can address this barrier and promote access. Successful uptake of generic medicines depends, in part, on ensuring that these products are interchangeable with reference products. Typically, bioequivalence certification is e...
    Acceso a Medicamentos Esenciales y Tecnologías Sanitarias, Política de Medicamentos Genéricos, Medicamentos Genéricos/provisión & distribución, Equivalencia Terapéutica, Industria Farmacéutica/organización & administración, Certificado del Registro de Productos, Chile
    Texto completo

    Evaluation of the effects of a generic substitution policy implemented in Chile

    Mansilla, Cristián; Cárdenas, Jorge; Kaplan, Warren A; Wirtz, Veronika J; Kuhn-Barrientos, Lucy; Zárate, Matías Ortíz de; Tobar, Tatiana; Herrera, Cristian A.
    BMJ Glob. Health; 4 (2), 2019
    Chile implemented a generic substitution policy in 2014 to improve access to medicines. This study aims to measure if the generic substitution policy had an effect on the sales volume and prices of referent and the branded generic products with demonstrated bioequivalence (BEQ) in the private pharmaceuti...
    Acceso a Medicamentos Esenciales y Tecnologías Sanitarias, Política de Medicamentos Genéricos, Equivalencia Terapéutica, Industria Farmacéutica/economía, Precio de Medicamento, Medicamentos Genéricos/economía, Chile
    Texto completo